



THE ELECTROCONVULSIVE THERAPY WORKBOOK

CLINICAL APPLICATIONS

ALAN WEISS

The Electroconvulsive Therapy Workbook

Electroconvulsive Therapy (ECT) remains one of the most effective forms of neurostimulation for severe mental illness. Sound scientific research underpins contemporary practice challenging the complex history and stigma that surround this treatment.

The Electroconvulsive Therapy Workbook integrates the history of ECT with major advances in practice, including ultrabrief ECT, in a hands-on workbook format. Novel forms of neurostimulation are reviewed, highlighting the future directions of practice in this exciting area. The book is also richly illustrated with historical and technical images and includes 'clinical wisdom' sections that provide the reader with clinical insights into ECT practice. Online eResources are also available, featuring a wide range of questions and answers related to each chapter to help test and consolidate readers' understanding of ECT, as well as regionally specific legislation governing ECT practice in Australia and New Zealand.

This comprehensive introduction to ECT is a must-read for doctors in training, psychiatrists who require credentialing in this procedure, anaesthetists, nursing staff who work in ECT and other professionals who have an interest in ECT as well as consumer and carer networks.

Alan Weiss is conjoint senior lecturer at the University of Newcastle, Australia. He is also a fellow of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) and chair of the Colleges Section for ECT and Neurostimulation (SEN); clinical director of the neurostimulation programme for the Hunter New England Local Health District; chair of the expert committee to revise 2010 NSW ECT Guidelines; and foundation director of neurostimulation at two private hospitals in Newcastle. Dr Weiss is a member of the International Society for ECT and Neurostimulation and the American Psychiatric Association.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

The Electroconvulsive Therapy Workbook

Clinical Applications

Alan Weiss

First published 2018
by Routledge
2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN

and by Routledge
711 Third Avenue, New York, NY 10017

Routledge is an imprint of the Taylor and Francis Group, an informa business

© 2018 Alan Weiss

The right of Alan Weiss to be identified as author of this work has been asserted by him in accordance with sections 77 and 78 of the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers.

Trademark notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

Names: Weiss, Alan, 1955 July 9– author.

Title: The electroconvulsive therapy workbook :
clinical applications / Alan Weiss.

Description: Abingdon, Oxon ; New York, NY : Routledge, 2018. |

Includes bibliographical references.

Identifiers: LCCN 2017056040 | ISBN 9781138713369 (hardback) |

ISBN 9781138713376 (pbk.) | ISBN 9781315198897 (ebook)

Subjects: | MESH: Electroconvulsive Therapy – methods

Classification: LCC RC485 | NLM WM 412 | DDC 616.89/122 – dc23

LC record available at <https://lcn.loc.gov/2017056040>

ISBN: 978-1-138-71336-9 (hbk)

ISBN: 978-1-138-71337-6 (pbk)

ISBN: 978-1-315-19889-7 (ebk)

Typeset in Palatino and Bell Gothic
by Florence Production Ltd, Stoodleigh, Devon, UK

eResources are available at www.routledge.com/9781138713376/



Contents

Preface	xvii
Acknowledgements	xix
1. Introduction	1
1.1 Overview	3
Purpose	3
Aims	5
Objectives	5
A competency-based ECT programme	5
1.2 Definition	11
1.3 Equipment	14
History: ECT devices	14
ECT device characteristics	19
2. Knowledge	21
2.1 History: treatment of mental illness	23
Trepanning: early psychosurgery?	23
Bloodletting	24
Pharmacology	25
Phrenology	26
Early 1800s	27
Electricity	29
2.2 History: ECT	33
Mental illness and convulsions	34
Negative images emerge	36
The media fans negativity	36
Unmodified ECT	37
The changing face of the media	38
The Bolam test	39

2.3 Major advances in ECT practice	42
Introduction of anaesthesia	43
<i>Induction agents</i>	43
<i>Muscle relaxants</i>	43
Hyperoxygenation and hyperventilation	43
Electrode placement	44
Ultrabrief ECT	45
Stimulus wave forms	45
Seizure threshold and stimulus dose titration	46
Electroencephalogram (EEG)	47
ECT: minimum standards and audit	48
The lived experience	48
2.4 Mechanism of action	53
Psychological hypothesis	54
Electrophysiological hypothesis	54
Neuroendocrine hypothesis	54
Neurochemical hypotheses	55
Anticonvulsive hypothesis	56
Neurogenesis hypothesis	56
Gene expression hypothesis	56
Cognitive effects of ECT	57
2.5 Clinical indications for ECT: adults	59
Major depressive disorder/unipolar depression	59
<i>Clinical practice guidelines (CPGs)</i>	61
United Kingdom (UK)	61
Scotland	62
Spain	62
World Federation of Societies of Biological Psychiatry (WFSBP)	62
USA	63
Canada	63
Australia	64
Bipolar disorder: mania, depression and mixed state	65
<i>Clinical practice guidelines (CPGs)</i>	66
United Kingdom (UK)	66
USA	66
World Federation of Societies of Biological Psychiatry (WFSBP)	66
Scotland	67
Canada	67
Australia	67
Schizophrenia	68
<i>Clinical practice guidelines (CPGs)</i>	69
Schizoaffective disorder	70
Catatonia	70
Neuroleptic malignant syndrome	71

Perinatal disorders	71
Parkinson's disease	72
Other diagnoses	73
2.6 Clinical indications: children and adolescents	80
History	80
Clinical concerns	81
Clinical indications	83
Major depressive disorder with melancholia and psychosis	83
Major depressive disorder with lethal suicide attempts/severe self-injurious behaviour (SIB)	84
Treatment-resistant depression and bipolar disorder in adolescents	84
Bipolar disorder unresponsive to mood stabilisers	85
Schizophrenia spectrum disorders (SSD)	85
Catatonia in children and adolescents	87
Tolerability of ECT in adolescents	87
Special considerations	88
2.7 Clinical indications: older people	92
Clinical concerns	92
Clinical indications	93
Tolerability of ECT in old age	93
Management special considerations	95
2.8 Efficacy of ECT	97
2.9 Contraindications for ECT	100
Mortality rate	100
Complex comorbidities	101
Cardiovascular risk	101
Risk of untreated psychiatric illness	101
Chemotherapy	102
Conclusion	102
2.10 Brain stimulation: new directions	104
Definition	105
Advantages of brain stimulation techniques	105
Convulsive stimulation techniques	106
<i>Magnetic seizure therapy (MST)</i>	106
<i>Focal electrically assisted seizure therapy (FEAST)</i>	107
Non-convulsive stimulation techniques	108
<i>Repetitive transcranial magnetic stimulation (rTMS)</i>	108
History of rTMS	109
Resting motor threshold	110
Patient set-up	111
Safety	111
rTMS stimulus parameters	112

Factors that affect efficacy of rTMS	112
rTMS in depression	112
rTMS in schizophrenia	113
rTMS as a clinical treatment option	113
RANZCP Position Statement 79: rTMS (RANZCP, 2013)	114
<i>Deep repetitive transcranial magnetic stimulation (dTMS)</i>	114
dTMS safety data	115
dTMS in psychiatric conditions	115
dTMS in other conditions	116
<i>Transcranial direct current stimulation (tDCS)</i>	116
Patient set-up	117
Other forms of transcranial electrical stimulation	118
Evidence base for tDCS	118
<i>Vestibular stimulation</i>	120
Caloric vestibular stimulation (CVS)	120
Galvanic vestibular stimulation (GVS)	121
<i>Evoked potentials (EP)</i>	121
Sensory evoked potentials	121
Visual evoked potentials (VEPs)	121
Short-latency brainstem auditory evoked potentials (BAEPs)	122
Somatosensory evoked potentials (SEPs)	122
Motor evoked potentials	122
Transcranial electrical motor evoked potential monitoring (TCeMEP)	122
Surgically invasive techniques	122
<i>Deep brain stimulation (DBS)</i>	122
DBS and Parkinson's disease	123
DBS and depression	124
DBS and obsessive compulsive disorder (OCD)	125
<i>Vagus nerve stimulation (VNS)</i>	125
VNS and intractable epilepsy	126
VNS and treatment-resistant depression	126
<i>Transcutaneous vagus nerve stimulation (t-VNS)</i>	127
<i>Direct cortical stimulation (DCS)</i>	128
<i>Navigated repetitive TMS (nTMS)</i>	128
<i>Pre-surgical functional magnetic resonance imaging (fMRI)</i>	
for language assessment	128
<i>Magnetoencephalography (MEG)</i>	129
Conclusion	129
3. Organisational/administrative skills	139
3.1 Setting up an ECT service/clinical governance	141
Approach to service delivery	142
ECT service goals	143
Communication	143

<i>ECT committee</i>	143
<i>ECT clinical guidelines</i>	143
<i>Database</i>	144
<i>ECT team</i>	144
<i>Team members</i>	144
Clinical director of ECT services	144
Psychiatry registrars/trainees	144
ECT coordinator/nurse specialist	145
Other team members	145
<i>Legislative framework</i>	145
<i>Consent</i>	145
<i>Equipment</i>	147
<i>Environment</i>	148
General hospital	148
Stand-alone ECT suite	148
<i>Initial assessment</i>	148
<i>ECT technique</i>	149
<i>Anaesthetic technique</i>	150
<i>Anaesthetic agents</i>	150
<i>Continuation and maintenance ECT</i>	151
<i>Audit</i>	151
<i>The lived experience</i>	151
4. Clinical skills	155
4.1 The sequence of ECT	157
Referral	157
Emergency ECT	158
The ECT journey	158
Measurement during ECT	159
Memory	159
Audit	160
ECT tapering/step-down	161
ECT record	162
4.2 Adverse events of ECT	164
Adverse events during ECT	164
Cardiovascular events	164
Asystole/electrocardiac pause	165
Oral and dental trauma	167
Fractures	168
Complications secondary to medication	168
Prolonged seizures	168
Adverse events immediately post-ECT treatment	170
Transient postictal delirium	170
Headaches	170

<i>Myalgia</i>	171
<i>Nausea and vomiting</i>	171
Adverse effects after the course of ECT treatment	172
<i>Cognitive disturbance</i>	172
Acute effects	173
Retrograde amnesia	173
Current debate: evaluating autobiographical memory	174
Conclusion	175
Anterograde amnesia	176
Subjective memory deficits	176
Fear of ECT	177
Other cognitive deficits	178
<i>Detection of cognitive deficits</i>	178
<i>Audio Recorded Cognitive Screen (ARCS)</i>	180
<i>Strategies to improve efficacy and minimise cognitive impairment</i>	180
4.3 Medical risks and management	187
Cardiovascular complications	188
<i>Pathophysiology</i>	188
<i>Clinical application</i>	189
<i>High-risk cardiovascular conditions</i>	189
<i>Management of the haemodynamic risk</i>	189
<i>Myocardial infarction (MI) and unstable angina</i>	190
<i>Cardiac pacemakers</i>	191
<i>Aneurysms</i>	191
Neurological disorders	191
<i>Cerebral infarction and haemorrhage</i>	191
<i>Intracranial pathology</i>	192
<i>Epilepsy</i>	192
<i>Multiple sclerosis</i>	192
<i>Myasthenia gravis</i>	192
<i>Skull defects and intracranial metal objects</i>	193
Neuropsychiatric disorders	194
<i>Dementia</i>	194
<i>Pseudodementia/depressive dementia</i>	195
<i>Neuroleptic malignant syndrome (NMS)</i>	195
<i>Parkinson's disease (PD)</i>	196
<i>Muscular skeletal disorders</i>	197
Endocrine	197
<i>Osteoporosis</i>	197
<i>Diabetes mellitus</i>	197
<i>Hypothalamic–pituitary–thyroid axis</i>	198
<i>Hyperthyroidism</i>	198
<i>Hypothyroidism</i>	198
<i>Chronic adrenal insufficiency (Addison's disease)</i>	199
<i>Other endocrine conditions</i>	199

Metabolic disorders	199
<i>Hyperkalemia</i>	199
<i>Hypokalaemia</i>	199
<i>Hyponatremia</i>	200
<i>Hypernatremia</i>	200
<i>Renal dialysis</i>	200
Other medical illnesses	200
<i>Eye pathology</i>	200
<i>Obesity</i>	201
<i>Dentition</i>	201
<i>Chronic obstructive pulmonary disease and asthma</i>	201
<i>Gastro-oesophageal reflux disease (GORD)</i>	202
<i>Urinary retention</i>	202
<i>Anticoagulation</i>	202
<i>Pseudocholinestase deficiency</i>	203
Pregnancy	203
<i>Anaesthetic considerations</i>	205
<i>Procedural modifications</i>	206
<i>Postnatal considerations</i>	206
<i>Breastfeeding</i>	207
4.4 Drug interactions	218
Antidepressants	219
<i>Tricyclic antidepressants (TCA)</i>	220
<i>Selective serotonin/noradrenaline reuptake inhibitors</i> <i>(SSRI and SNRI)</i>	221
<i>Noradrenaline reuptake inhibitors</i>	221
<i>Agomelatine</i>	221
<i>Trazodone</i>	221
<i>Monoamine oxidase inhibitors (MAOI)</i>	221
<i>Bupropion (Zyban)</i>	222
Benzodiazepines	222
Antipsychotic medication	223
<i>Clozapine</i>	224
Mood stabilisers	225
<i>Anticonvulsant medication</i>	225
<i>Lamotrigine</i>	225
<i>Anticonvulsants and epilepsy</i>	226
<i>Lithium</i>	226
Other drugs	227
<i>Caffeine</i>	227
<i>Theophylline</i>	228
<i>Antihypertensive agents</i>	228
<i>Digoxin</i>	228
<i>Diabetic medication</i>	228
<i>Acetylcholinesterase inhibitors</i>	228
Australian psychotropic therapeutic guidelines	229

4.5 Tips for clinical practice	234
Background	234
Stigma or no stigma?	236
To talk or not to talk?	236
Operating theatre or stand-alone suite?	236
To titrate or not to titrate?	238
To clean or not to clean?	238
Disposable or handheld electrodes?	239
To monitor or not to monitor?	240
<i>Electromyogram (EMG)</i>	241
<i>Cuff monitoring</i>	241
<i>Awareness</i>	241
<i>Electrocardiogram (ECG)</i>	241
<i>Deep tendon knee reflex</i>	241
<i>Nerve stimulator</i>	242
To measure or not to measure?	242
Ultrabrief or not ultrabrief?	242
What next after ultrabrief?	243
Twice a week or three times a week?	244
To restrain or not to restrain?	244
<i>Before ECT</i>	244
<i>After ECT</i>	245
To time or not to time?	245
To treat or not to treat?	245
To continue or not to continue?	247
Which device: MECTA or Thymatron?	247
Conclusion	248
5. Technical skills	251
5.1 ECT technique	253
Basic steps	253
Isolated limb technique (ILT)	254
Treatment steps	256
Monitoring electrodes anatomical placement	257
<i>Thymatron System IV</i>	257
Placement of electrodes	258
Electrode site skin preparation	258
Apply treatment electrodes	260
Testing impedance	260
<i>Thymatron System IV</i>	260
<i>MECTA spECTrum 5000</i>	261
Oxygenation/hyperventilation	261
Protection of the oral cavity	262
Time out	263
Anaesthetic technique	264

Administration of anaesthetic agents	264
Delivery of stimulus	264
<i>Thymatron System IV</i>	264
<i>MECTA spECTrum 5000</i>	264
Procedure post-seizure	265
Recovery	265
Missed or abortive seizures	265
<i>Missed seizures</i>	265
<i>Abortive seizures</i>	266
5.2 Electrode placement	267
History	268
Current practice	268
Ultrabrief ECT	268
Landmarks	270
Right unilateral ECT non-dominant (RUL)	270
“Handedness” or laterality	272
Left unilateral electrode placement (LUL)	273
Bitemporal ECT (BT)	274
Bifrontal ECT (BF)	275
Left anterior right temporal (LART)/left frontal right temporal (LFRT) ECT	278
Other electrode placements	280
Recommendations for clinical practice	280
Unipolar and bipolar depression	280
Schizophrenia	281
5.3 Stimulus dosing strategies	286
Current debate concerning dosing strategies	287
Fixed high-dose strategy	287
<i>The evidence</i>	287
Age-based dose strategy	288
Half-age dose strategy	288
Stimulus dose titration	288
Changing the stimulus dose	288
Dose based upon multiple factors	291
<i>Benchmark method</i>	291
<i>Other methods</i>	292
5.4 The stimulus	293
Stimulus parameters	293
The ECT electrical circuit	295
Impedance	295
Charge	296
Energy	296
Charge-rate	297

The action potential	297
Inappropriate stimuli	298
Constant current	298
Wave form	299
Pulse width	300
<i>History</i>	300
<i>Current practice</i>	301
Inter-pulse interval	301
Stimulus train	301
Frequency	302
Amplitude	302
Stimulus dose	303
Seizure threshold	303
EEG "therapeutic window"	304
Stimulus dose titration	305
Combined titration and treatment	306
Subconvulsive stimulation	306
<i>Cardiovascular disease</i>	306
<i>Cognitive impairment</i>	307
5.5 The electroencephalogram (EEG)	311
Overview	311
Definition	312
Physiology	313
Categorisation of bandwidths	313
EEG properties	314
Gain	314
Workbook EEG traces	315
Phases of the ictal EEG	315
The ictal line	320
Electrocardiogram (ECG)	320
Measurement of the motor fit	321
Summary	321
Markers of seizure adequacy	323
<i>MECTA spECTrum 5000</i>	323
<i>Thymatron System IV</i>	324
The future	324
EEG artefacts	326
Conclusion	327
5.6 Anaesthesia for ECT	329
Anaesthetic technique	329
Anaesthetic agents	331
<i>Anticholinergic agents</i>	331
<i>Induction agents</i>	331
Barbiturates	331

Propofol	332
Opioids	332
Ketamine	332
Etomidate	333
Sevoflurane	333
Muscle relaxants	333
<i>Suxamethonium or succinylcholine</i>	334
<i>Non-depolarising muscle relaxants</i>	334
Equipment	334
Day-only procedures	335
Recovery	336
Hyperoxygenation	336
Mouth protection	337
<i>Bite blocks</i>	337
Disposable/single-use bite blocks	337
Re-useable/rubber bite blocks	337
5.7 ECT devices: set-up procedure	340
Thymatron System IV	340
<i>For power settings above 100% without ultrabrief pulse width (0.3 ms) modification</i>	344
<i>Safety monitor activated alarm</i>	344
<i>For power settings above 100% with ultrabrief pulse width (0.3 ms) modification</i>	344
MECTA spECTrum 5000M and Q	344
Thymatron DGx	347
6. Ambulatory ECT, continuation ECT and maintenance ECT	349
6.1 ECT after completion of the index course	351
Ambulatory ECT	351
<i>Patient monitoring</i>	352
Tapering or step-down ECT	353
Continuation ECT	353
Maintenance ECT	353
Indications for continuation and maintenance ECT	353
Current state of the evidence	354
The literature	354
Maintenance ECT schedule	356
The end point for maintenance ECT	357
<i>Physical assessment</i>	357
<i>Cognitive assessment</i>	357
<i>Case conference</i>	357
<i>Day of treatment</i>	358

7. The ECT nurse and the ECT coordinator	361
7.1 Nurses: key members of the ECT team	363
Nursing involvement in the ECT journey	363
ECT ward nurse	364
ECT admissions nurse	365
ECT recovery nurse	365
ECT nurse	367
ECT coordinator	367
8. ECT: the lived experience	369
8.1 Consumer perspectives	371
<i>Wow I have my life back!</i> By Alirra	373
9. Scenario-based problems	379
9.1 Postictal delirium and ECT	381
9.2 ECT, the elderly and a high seizure threshold	386
9.3 ECT, epilepsy and obsessional personality style	393
9.4 Fear of ECT	399
9.5 Complex ECT treatment: identify errors and make recommendations for improvement	407
9.6 EEG challenges: what should you do next?	411
Case 1: 19-year-old female, suprathereshold seizure	411
Case 2: 42-year-old male, threshold seizure	413
Case 3: 84-year-old female, poor-quality EEG	416
Case 4: 36-year-old female, fifth treatment with short EEG	418
Index	421



Preface

Electroconvulsive Therapy (ECT) remains one of the most effective treatments for severe mental illness. It has a complex history that continues to stigmatise and distract from the large number of changes in technology and methods that have made it a modern treatment. Modern ECT practice is based upon sound scientific research generating a substantial evidence base that guides treatment. However, there continues to be a gap between the clinicians who administer ECT and its consumers and a failure of ECT practitioners to implement novel techniques.

Training provided to doctors administering ECT worldwide has been inadequate and highly variable. International audits have highlighted a lack of expertise and resources in this area. In 2003, the UK's National Institute for Health and Clinical Excellence (NICE) Guidance Document for ECT was very critical of ECT practice, stating that ECT should be a "treatment of the last resort", a criticism that may have merit owing to the vast difference between clinicians' and consumers' perspectives of ECT. Staff administering ECT often have superficial training before they are expected to administer the treatment in their hospital.

The Electroconvulsive Therapy Workbook is a book for clinicians and trainees of all disciplines who practise ECT. It is not a Royal College or Association clinical practice guideline or an academic work but a comprehensive approach to ECT that emphasises knowledge in an environment that challenges prejudice and stigma, incorporates new techniques to minimise unwanted side effects and maximise the benefits of ECT.

The Electroconvulsive Therapy Workbook has been the result of two major influences: 22 years of listening to patients undergoing ECT and using their experiences to change practice through the development of a competency-based ECT training programme for doctors, nurses and students working in the area of ECT. The competency-based learning model provides a structured approach to ensure that trainees who complete the ECT Entrustable Professional Activities (EPA) programme have a high level of technical skills and the ability to engage with patients undergoing ECT in an empathic manner, closely monitoring progress and making changes in treatment to minimise adverse reactions. There is an emphasis on training in a multidisciplinary setting that places the ECT team at the core of treatment. *The ECT Workbook* is an integral part of this programme, anchoring learning in sound clinical practice.

The ECT Workbook offers practical information, supported by recent evidence, concerning the clinical application of ECT in psychiatric practice throughout the world. Information is broken down into relevant sections using a workbook format: overview, definition, knowledge (ranging from past history to major advances), mechanism of action, clinical indications, efficacy, neurostimulation techniques, organisational

and administrative skills, clinical skills, technical skills, anaesthesia, maintenance ECT, the lived experience, the role of the ECT nurse and detailed scenario-based problems.

Relevant chapters are illustrated with historical, technical photos and figures to aid learning with a question and answer format following most chapters. Many sections include a “clinical wisdom” insert that offers advice where there is limited evidence to guide treatment drawing upon extensive practice-based experience in the administration of ECT.

After reading this volume it is anticipated that the reader will have a comprehensive understanding of current ECT practice and feel equipped to challenge stigma by implementing change into the way ECT is delivered in their service.

Dr Alan Weiss
Newcastle, NSW, Australia



Acknowledgements

The Electroconvulsive Therapy Workbook would not have been possible if it were not for the tireless and unyielding support from my wife, Ann, and my three daughters, Ella, Danika and Petra. Thank you Ella and Caitlin for your early inspiration and your support in helping me type and design the original manuscript that provided the framework for *The Electroconvulsive Therapy Workbook*.

I would like to thank all of the patients that I have treated with ECT over many years who have shared their lived experience, inspiring me to develop an ECT service and training programme with a strong focus on eliminating stigma, using modern techniques that minimise cognitive impairment while striving to achieve complete remission. In particular, I would like to thank Alirra for bravely agreeing to share her moving and personal account of ECT from the first moments through to maintenance treatment.

A big thank you goes to Shane and the ECT team at the Mater Hospital, Newcastle, Australia. This team forms the basis of the ECT training programme. Shane has provided endless support over many years to myself and countless trainees and has become a vast store of clinical wisdom concerning ECT practice. I am indebted to Shane who helped me write the chapter on the ECT nurse and his inspiration and encouragement to continue with this large and at times overwhelming project.

A special thank you goes to Doctor Michael, a vibrant and enthusiastic senior psychiatry fellow who is passionate about his patients, ECT and neurostimulation. Doctor Michael's enthusiasm and support has been inspirational in the writing of *The Electroconvulsive Therapy Workbook*, reinforcing my own passion to administer ECT in a manner that minimises stigma, is patient-focused and patient-responsive, and has a strong evidence base with the capacity to incorporate practice-based experience to ensure that patients benefit from this powerful treatment with the least possible side effects.

The Electroconvulsive Therapy Workbook would not have been as colourful and informative if it were not for Luke, who generously consented to model for all photographs in this volume. It is refreshing to incorporate the difference in his presentation between the two photo shoots that occurred many months apart echoing the enormous diagnostic, psychosocial and cultural difference in patients who are given ECT.

I am most grateful to Doctor John Fluit for opening up his fantastic medical history museum and providing all of the historical photos that grace this Workbook. I am indebted to him for assisting in writing Section 2.1 History: treatment of mental illness.

I would like to acknowledge and thank Amber for her inspiration and innovation in the drawings and figures that are used to simplify and clearly explain different concepts used in this *Workbook*.

I am indebted to the staff at Hudson Street Specialist Centre, who provided support and assistance during the long period of time it has taken to complete this work.


I would like to thank the staff and psychiatrists who work at Lakeside Clinic, Warner's Bay Private Hospital, Newcastle, Australia, who have provided encouragement and support, reinforcing that the techniques incorporated in *The Electroconvulsive Therapy Workbook* are effective in reducing stigma, minimising cognitive problems and achieving remission in a patient-focused supportive environment that is responsive to clinical change.

I would like to thank Robin, CEO MECTA Corporation, for generously providing photographs and historical content that enhances this *Workbook*.

I wish to acknowledge Magventure for making available a photograph of their new Magpro MST device.

Finally I wish to make a posthumous acknowledgement to Mr Ian Maudsley, the foundation ECT coordinator within Hunter New England Local Health District, NSW, Australia. Ian's huge drive and tireless work have irreversibly changed the role of nurses in ECT services internationally. His willingness to step up to the challenge and engage with nurses from around the world was instrumental in nursing becoming a valued member of the International Society for ECT and Neurostimulation (ISEN). If it were not for his contribution, the prominence of nursing in the local ECT training programme for medical and nursing staff would not have been as great. Ian Maudsley inspired me to describe the ECT coordinator as the "powerhouse" of the ECT team. Thank you from the bottom of my heart. I miss your charm, humour and sophistication.

Dr Alan Weiss



CHAPTER 1

Introduction



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Overview

■ Purpose	3
■ Aims	5
■ Objectives	5
■ A competency-based ECT programme	5

PURPOSE

Electroconvulsive Therapy (ECT) is a treatment that has a complex history. It was first used in 1938. Since that time, many advances have been made in the practice of ECT and the science behind this very effective treatment for severe mental illness.

For many years, the training of doctors and other staff administering ECT was inadequate and highly variable. Medical staff administering this treatment often had very superficial training before they were expected to administer the treatment in their hospital.

Duffett and Lelliott (1998) commented that after a 20-year period only modest improvements in the local practice of ECT within England and Wales were demonstrated, after the Royal College of Psychiatrists (RCP) completed its third large-scale audit. These audits were very extensive and were followed by specific recommendations for change highlighting a lack of expertise and resources that were allocated to the provision of ECT.

Significant changes have been made since the release of National Institute for Health and Care Excellence (2003) guidance on ECT for depressive illness, schizophrenia, catatonia and mania. This document was based upon two systematic reviews sponsored by the Department of Health; UK ECT Review Group (2003) and Rose, Fleischmann, Wykes, Leese and Bindman (2003) highlighted the consumer’s viewpoint. Following these reviews, the guidance for ECT was very critical, stating:

ECT should be used only to achieve rapid and short-term improvement of severe symptoms after adequate trials of other treatments have failed when the condition is considered to be potentially life-threatening with, severe depressive illness, catatonia or a prolonged or severe manic episode. The current state of the evidence does not allow the general use of ECT on the management of schizophrenia to be

recommended as the long-term benefits and risk of ECT have not been clearly established, it is not recommended as a maintenance therapy in depressive illness. ECT should be used as a treatment of last resort.

(NICE, 2003)

This guidance was met with strong criticism from psychiatrists within the UK and around the world, as they were not consistent with the common clinical use of ECT in the everyday treatment of depression. The *ECT Handbook*, 2nd edition (Scott, 2005) was revised to address the criticisms raised by the NICE guidance document and released as *The ECT Handbook*, 3rd edition (Waite and Easton, 2013).

More recently, the Royal College of Psychiatrists released the *ECT Accreditation Service (ECTAS): Standards for the Administration of ECT*, 12th edition (Royal College of Psychiatrists, 2015), which specifies minimum standards of practice. Australia and New Zealand have followed this lead, with many states making a considerable effort to review ECT practice by developing minimum standards guidelines (Chief Psychiatrist of Western Australia, 2015; NSW Health, 2010; SA Health, 2014; Victorian Government, 2014).

It was within this environment that *The Electroconvulsive Therapy Workbook* evolved over a 16-year period as part of a competency-based ECT training programme for staff working in this area.

CLINICAL WISDOM 1.1.1

One of the most distressing encounters that junior house staff and psychiatric registrars have to deal with when completing studies in psychiatry is their encounter with the relevant mental health legislation, which often involves dealing with an independent mental health review tribunal (MHRT) in the state/territory in which they practise. In many instances this creates significant ethical concerns within the individual about the pros and cons of administering psychiatric treatment to patients who are unable to provide informed consent.

The adversarial model is particularly paramount in some jurisdictions where the consumer/patient is entitled to legal representation whereas the medical arguments are often presented by a junior member of the medical team. The medical argument necessarily involves breaking the confidence of the patient by expanding the content of significant past events, psychotic delusions or self-harming behaviour. This process can create distress in the doctor who has limited academic knowledge, clinical and legal experience and a superficial understanding of complex clinical details.

The dilemma is magnified when the doctor is also required to ask for a determination to administer a course of ECT. It is not until some time later, when the doctor has followed a number of patients through a course of ECT, that they understand the marked and rapid clinical improvement that occurs with this treatment, providing meaning to what can often be a hostile and unpleasant experience.

The process becomes even more complex as the adversarial model challenges the fundamental core skill of psychiatry, namely establishing a good therapeutic alliance with the patient (Bellis, 2016; Martin, Garske and Davis, 2000). The registrar is obliged to reveal complex, detailed personal information in a semi-legal setting to enable the tribunal to make a determination. This fundamental breach of confidence usually results in the patient resenting the doctor, and often will be reluctant to speak to them for the remainder of the admission if the tribunal has determined that ECT is necessary.

The junior psychiatric registrar can be left feeling disillusioned, confused and angry as this process is at odds with their early impression of psychiatry as a profession that is altruistic, nurturing and caring. The ethical challenge is so intense that it often leads to early withdrawal from the training programme.

This phenomenon is well recognised and has led to the development of some innovative strategies to empathise with the new trainee, like *The Hitchhikers Guide to Psychiatry* (Varmos, 2008).

There are four guiding principles that can assist in navigating this difficult road. These principles are guided by the basic tenets of ethics (Bloch and Singh, 2001). They include:

- Beneficence: do good; maximise efficacy.
- Non-maleficence: do no harm; minimise side effects and reduce stigma.
- Autonomy: respect patient; ensure that individual wishes and differences are considered.
- Justice: equality; ensure that there is equal opportunity for treatment regardless of age, gender, colour, religion or wealth in the least restrictive environment (Bloch and Singh, 2001).

Application of these principles has formed the basis of clinical practice over many years, particularly in ECT, enabling difficult situations, ethical dilemmas and conflict situations to be overcome and resolved. Fink (2009) provides a more detailed and helpful discussion of these principles as they apply to ECT.

All medical practice seeks to optimise benefits and minimise risks by ensuring a high level of competency in staff administering the treatment. The ECT technique can have a substantial impact on clinical outcome, particularly cognitive impairment (Sackeim et al., 2007). The benefits of modern ECT are well defined and substantial, offering severely unwell patients a chance to recover in modern settings that provides autonomy, justice and beneficence.

ECT worked for me, not that it will work for everyone. . . . We need to face up to ECT's risk and try to reduce them, but we need to acknowledge its potential benefits. . . . There are too many people in desperate need of a workable treatment to limit any viable options.

(Dukakis and Tye, 2006)

AIMS

The aims of the Electroconvulsive Therapy training programme are set out in Table 1.1.1.

OBJECTIVES

The objectives of the Electroconvulsive Therapy training programme are set out in Table 1.1.2.

A COMPETENCY-BASED ECT PROGRAMME

A recent initiative in postgraduate medical education is competency-based learning with the use of modules incorporating entrustable professional activities (EPA) (Cate and Sheele, 2007). An EPA is defined as an activity or procedure that should only be carried out by a trained specialist who

achieves a level of competency in a range of special skills that are fundamental to the procedure. ECT is a good example of an EPA. Such a programme was first described in the Netherlands to help supervisors determine the competency of their trainees (Scheele et al., 2008). Supervisors consider whether or not to delegate professional activities to trainees by determining whether they feel confident to trust a trainee to perform a specialised task with specific independence. At completion the trainee knows when to ask for additional help and can be trusted to seek assistance in a timely manner (Cohen and Port, 2012).

Competency-based training and assessment is the term used in the education literature that closely examines what actual tasks a person has to perform in the “workplace” in the role for which they are being trained and then ensuring that the required

Table 1.1.1 Aims

-
- Provide an overview of the historical context surrounding the practice of ECT
 - Provide an understanding of how the community has been influenced by the media, resulting in shame, stigma and marginalisation of ECT practice
 - Identify the changes that have occurred in ECT practice since its inception as the first neurostimulation technique
 - Understand the science and research that underpin modern ECT practice
 - Understand local protocols and procedures that determine ECT practice
 - Understand the legal principals as they apply to the relevant Mental Health Act that governs the practice of ECT in the local region, with an emphasis on adequate informed consent
 - Understand the clinical context in which modern ECT is utilised
 - Understand the indications for ECT as well as the necessity for a comprehensive history, physical examination, appropriated investigations and mandatory cognitive and diagnostic measures
 - Understand how to proceed with high-risk populations and special precautions that are required
 - Be familiar with all aspects of anaesthesia
 - Understand the rationale for monitor, role of the “time out procedure” and evaluation during and after the treatment
 - Understand dosing protocols, procedures and rationale for different electrode placements
 - Develop confidence in interaction with patients, careers and the ECT team
 - Demonstrate an ability to obtain informed consent and the importance of involving family and careers when treatment is voluntary
 - Ability to present a patient to the relevant mental health review tribunal to request an authorization to commence ECT
-

skills are taught and assessed in training (Cate and Sheele, 2007; Cohen and Port, 2012; Scheele et al., 2008). In particular, competency refers to the demonstrated ability of the person being trained to actually perform the important learned tasks, at the required level in the workplace (Cate and Sheele, 2007). It is known that knowledge alone does not ensure a competent practitioner. It also requires the right attitude and a number of practical skills for the task required.

In recent years this approach to medical education has been applied to ECT. The ECT competency-based training programme has been designed to provide “hands-on” learning for candidates over a six-week period. In addition to having hands-on experience treating many patients, there is also a self-discovery or experiential session with the aim of giving the trainee the experience of being the patient. This “getting your hands dirty” session is conducted once during the training period (often

when the patient list is short). The aim is to give each trainee the experience of being the psychiatrist administering the treatment and then being the patient by simulating ECT treatment in theatre.

The ECT team has found that this experience provides the trainee with a personal experience of simulating ECT practice in situ as well as a snapshot of the patient’s experience of the treatment. Feedback from trainees has consistently highlighted the value of this programme component, which is practical and a lot of fun.

At completion of the EPA the trainee will be proficient in the modern use of ECT, demonstrating proficiency in all of the expected tasks associated with the prescription, administration and monitoring of ECT and able to complete the medical competency form.

The ECT Workbook provides the framework for an ECT EPA where trainees have to complete a case-based discussion (CbD) critically examining

Table 1.1.2 Objectives

- Describe the history and recent innovations in ECT practice and treatment
- Describe brain neuromodulation with specific reference to neurostimulation
- Define ECT, highlighting its benefits and limitations in a concise way to challenge public perceptions of this very effective but misunderstood treatment
- Describe the indications and contraindications for ECT
- Demonstrate an awareness of and appropriate management of medical comorbidities
- Describe situations of increased risk associated with ECT and how to manage them
- Describe complications of ECT and their management
- Describe the principles of stimulus dose titration, the strengths and limitations of this technique and alternative dosing strategies
- Demonstrate a detailed knowledge of the techniques in administering different types of ECT
- Demonstrate an ability to identify and measure the correct anatomical sites for recording and treatment electrodes for different types of ECT
- Demonstrate an ability to adequately prepare all electrode and treatment sites for all forms of electrode placement
- Describe the difference between different electrode placements, highlighting strengths and weakness
- Describe the different types of ECT highlighting the benefits and limitations of each method
- Understand potential drug interactions with ECT
- Understand the basic science and research evidence that underpin ECT
- Administer different types of ECT in a competent and professional manner
- Demonstrate basic knowledge of EEG monitoring and the relevant parameters involved in clinical decision-making
- Demonstrate an ability to work with the ECT team, recognising the specific tasks and roles of each team member
- Identify the challenges that are encountered in setting up an ECT service
- Describe the principles involved with ECT anaesthesia and recovery
- Describe the rationale behind using different induction agents and their impact on the quality of ECT administered
- Demonstrate an ability to liaise with inpatient and community teams concerning relevant issues involved with the delivery of ECT

the use of ECT in either an acute or chronic patient. At completion of the module the ECT coordinator conducts a workplace assessment by completing a direct observation of procedural skills (DOPS) form. The candidate gives a PowerPoint presentation on a ECT topic that is clinically relevant and of interest to them. The final assessment is the completion of an open book exam followed by an interactive discussion of the results. All questions are taken out of *The Electroconvulsive Therapy Workbook*. Robust discussion is more important to complete the EPA than the final test score.

CLINICAL WISDOM 1.1.2

It is not an exaggeration to say that ECT has opened a new reality for me. I used to deny when a depressive episode was coming on, to others and myself. I just could not face it. I thought if I ignored it, it might go away on its own. Now I know there is something that will work and work quickly. It takes away the anticipation and the fear. . . . It has given me a sense of control, of hope.

(Dukakis and Tye, 2006)

■ **Table 1.1.3** Medical Competency Checklist

<i>Competency criterion</i>	<i>Competent</i>	<i>(tick)</i>	<i>Comments</i>
Knowledge			
History	_____	_____	_____
Recent developments	_____	_____	_____
Legal aspects/legislation	_____	_____	_____
Drug interactions	_____	_____	_____
Clinical indications	_____	_____	_____
Risk situations	_____	_____	_____
The sequence of ECT	_____	_____	_____
Adverse events	_____	_____	_____
Anaesthesia	_____	_____	_____
Other	_____	_____	_____
Administrative skills			
Clinical governance	_____	_____	_____
Treatment schedule	_____	_____	_____
ECT facilities	_____	_____	_____
ECT documentation	_____	_____	_____
Clinical skills			
Patient interaction	_____	_____	_____
Staff interactions	_____	_____	_____
Informed consent	_____	_____	_____
Patient rapport	_____	_____	_____
Communication with staff	_____	_____	_____
Technical skills			
ECT clinical pathway	_____	_____	_____
ECT technique	_____	_____	_____
Equipment	_____	_____	_____
Basic steps			
Set dose/charge	_____	_____	_____
Skin preparation	_____	_____	_____
Cuff monitoring/ILT	_____	_____	_____
Monitoring lead placement	_____	_____	_____
Treatment lead placement	_____	_____	_____
Testing impedance	_____	_____	_____
Baseline determination	_____	_____	_____
Labelling the trace	_____	_____	_____
Role of anaesthetic agents	_____	_____	_____
Team consultation about current treatment	_____	_____	_____
Pre deep tendon knee reflex (DTKR)	_____	_____	_____
Observe fasciculations	_____	_____	_____
Post DTKR	_____	_____	_____
Recheck impedance	_____	_____	_____
Ensure mouth guard placement	_____	_____	_____
Team consent to treat	_____	_____	_____
Administer ECT	_____	_____	_____

Table 1.1.3 continued

<i>Competency criterion</i>	<i>Competent</i>	<i>(tick)</i>	<i>Comments</i>
Stimulus dosing			
Titration protocol	_____	_____	_____
Determining dose/charge	_____	_____	_____
Dosing strategies:			
Stimulus dose titration	_____	_____	_____
Stimulus parameters:			
Pulse width	_____	_____	_____
Seizure threshold	_____	_____	_____
Subconvulsive stimulation	_____	_____	_____
Electroencephalogram (EEG)			
EEG wave forms	_____	_____	_____
Phases of EEG	_____	_____	_____
Interpretation of EEG	_____	_____	_____
When to change dose	_____	_____	_____
Markers of seizure adequacy:			
• Postictal suppression index (PSI)	_____	_____	_____
• Average seizure energy index (SEI)	_____	_____	_____
• Maximum sustained power (MSP)	_____	_____	_____
• Maximum sustained coherence (MSC)	_____	_____	_____
Impedance – static/dynamic	_____	_____	_____
EEPRS	_____	_____	_____
EEG artefacts	_____	_____	_____
Electrode placement (EP)			
Choice of EP	_____	_____	_____
Right/left unilateral	_____	_____	_____
Bifrontal	_____	_____	_____
Bitemporal	_____	_____	_____
Left anterior right temporal	_____	_____	_____
Criteria for altering EP	_____	_____	_____
New directions			
Magnetic seizure therapy	_____	_____	_____
Transcranial magnetic stimulation	_____	_____	_____

Trainee comments: _____

Signature: _____

Director of ECT comments: _____

Signature: _____

ECT coordinator's comments: _____

Signature: _____

Date: _____

REFERENCES

- Cate, O.T., and Sheele, F. (2007). Entrustable professional activities. (EPA). *Academic Medicine*, 82, 542–547.
- Chief Psychiatrist of Western Australia. (2015). Chief Psychiatrist's practice standards for the administration of electroconvulsive therapy. Retrieved from www.chiefpsychiatrist.wa.gov.au/wp-content/uploads/2015/2/CP_ECT_Standards_2015.pdf.
- Cohen, M., and Port, N. (2012). Competency based fellowship program (CBFP) for supervisors workshop: overview of the CBFP. Hunter New England Local Health District, Newcastle, Australia. Retrieved from www.ranzcp.org/trainingprogram.aspx.
- Duffett, R., and Lelliott, P. (1998). Auditing electroconvulsive therapy. The third cycle. *British Journal of Psychiatry*, 172(5), 401–405. Retrieved from www.ncbi.nlm.nih.gov/pubmed/9747401.
- NICE. (2003). *Guidance on the Use of Electroconvulsive Therapy (Vol. Guidance Number 59)*. London: National Institute for Health and Care Excellence; National Health Service.
- NSW Health. (2010). ECT minimum standard of practice NSW. Retrieved from www.health.nsw.gov.au/policies/pd/2011/pdf/PD2011_003.pdf.
- Rose, D., Fleischmann, P., Wykes, T., Leese, M., and Bindman, J. (2003). Patients' perspectives on electroconvulsive therapy: systematic review. *British Medical Journal*, 326(7403), 1363. doi:10.1136/bmj.326.7403.1363.
- Royal College of Psychiatrists. (2015). *ECT Accreditation Service (ECTAS): Standards for the Administration of ECT*, 12th edition. London: Royal College of Psychiatrists.
- SA Health. (2014). South Australian guidelines for electroconvulsive therapy. Retrieved from www.sahealth.sa.gov.au/wps/wcm/connect/0608270046ad5b01b89.
- Scheele, F., Teunissen, P., Van Luijk, S., Heineman, E., Fluit, L., Mulder, H., . . . Hummel, T. (2008). Introducing competency-based postgraduate medical education in the Netherlands. *Medical Teaching*, 30(3), 248–253. doi:10.1080/01421590801993022.
- Scott, A.I.F. (2005). *The ECT Handbook*, 2nd edition. London: Royal College of Psychiatrists.
- UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet*, 361, 799–808.
- Victorian Government. (2014). Mental Health Act 2014 handbook. Retrieved from www.health.vic.gov.au/mentalhealth/mhact2014.
- Waite, J., and Easton, A. (2013). *The ECT Handbook*, 3rd edition. London: Royal College of Psychiatrists.

Definition

ECT is a treatment that has spanned nearly 80 years. During that time it has been given many different names, including Electroconvulsive Therapy (ECT), electroseizure therapy (EST), electoshock and convulsive therapy (CT) (Fink, 2009). Some of these names were not accurate and contributed significantly to the stigma associated with the treatment. Fink (2009) notes that electroshock is not an accurate term as there is no shock involved in ECT. It originated in 1933, when insulin was first used to treat schizophrenia and patients did show classic signs of “surgical shock”, including sweating, pallor and lowered levels of consciousness, and it was called insulin shock treatment. Seizure therapy, known as convulsion therapy, followed a year later, with the electrical induction of seizures in 1938 being termed “Electroshock” (Fink, 2009). Electroconvulsive Therapy (ECT), now the preferred name, has been used more recently to describe the treatment.

Over the years, the term shock treatment has remained popular and used by the media to gain immediate attention and instant recognition following its use in the movie *One Flew Over the Cuckoo's Nest* (Kesey, 1962). The term continues to be used by the media to stigmatise and denigrate the treatment (Bucci, 2009; De Brito, 2004) or portray a more balanced report (Brockie, 2013; Morrison, 2009). The popularity of the term is reflected in the book *Shock: The Healing Power of Electroconvulsive Therapy* (Dukakis and Tye, 2006), which provides a balanced view of ECT, interweaving the history of

ECT with a positive account of a consumer's personal experience of the treatment that saved her life. Unfortunately the term “shock” carries with it the notion that the treatment is painful, an image that is widely used by the Citizens Commission on Human Rights, established in 1969, to “investigate and expose criminal and abusive practices of psychiatrists” (Church of Scientology, 2015).

Painful electric shocks were used as aversion therapy as part of the early developments of operant conditioning (Wilson and Davison, 1969). Operant conditioning was a technique that used positive stimuli to reward positive behaviours and negative stimuli to inhibit unwanted or negative behaviours like headbanging, unwanted screaming in intellectually disabled patients and self-injurious behaviours. The initial stimulus for aversion conditioning was chemical and its move into painful electric shocks was controversial (Wilson and Davison, 1969).

As the science of psychology progressed, aversion therapy was applied to a range of other “deviant” behaviours: homosexuality and other sexual deviations (Feldman, 1966), compulsive gambling (Barker and Miller, 1968) and changing the sexual object choice through controlling masturbation (Marquis, 1970). The stigma associated with these abandoned and now discredited treatments fuels the persistent stigma associated with ECT (Torpey, 2016).

Further confusion comes from “electroconvulsive shock” (ECS), a term used to describe the

CLINICAL WISDOM 1.2.1

One of the biggest challenges that ECT faces in modern times is the stigma that remains prevalent throughout the community. The multiple terms and definitions that have been applied to this treatment have actively contributed to this prejudice. The advent of neuromodulation and more specifically neurostimulation has placed ECT into a context that enhances understanding of how it works challenging misinformation enabling the development of new and more focal techniques like Focal Electrical Administered Seizure Therapy (FEAST).

experimental induction of seizures in animals models that were designed to maximise the concordance of experimental animal studies with the clinical use of ECT (Nutt and Glue, 1993).

The journal *Convulsive Therapy* was established in April 1985 to provide a scientific platform for ECT research and discussion (McCall, Kellner and Fink, 2014). The foundation editor focused on convulsive therapy rather than other, more stylish areas of research because the practice was being actively challenged by both professionals and public attacks. Governments in many states and countries around the world condemned the practice enthused by the many new drugs and new forms of psychotherapy that were being developed to treat depression and psychosis (McCall et al., 2014).

The journal was called *Convulsive Therapy* as this was the most descriptive and least pejorative term when compared to other common terms used to describe ECT at that time, “shock therapy, electroshock and seizure therapy” (McCall et al., 2014). The goal of the journal was to provide a forum for ongoing debate and argument, systematic observation, comparison, deduction and verification of experiences with seizures and psychotic behaviour (Fink, 1985). Over the years, ECT has embraced modern anaesthetic practice, which has largely abolished the convulsion, the outward




Photo 1.2.1 Aversion stimulator

muscular manifestations of a seizure. Acknowledging this change in clinical practice and the increased trend to call the procedure ECT to overcome stigma, the journal changed its name to the *Journal of ECT* in 1998 (McCall et al., 2014).

Electroconvulsive Therapy has been defined as a medical procedure that involves the electrical induction of a series of generalised grand mal seizures, under general anaesthesia, with the specific aim of bringing about therapeutic remission in patients suffering from episodes of specific mental disorders such as major depression, mania and certain types of schizophrenia. Contrary to the views expressed by critics of the procedure, ECT is not subconvulsive electrical stimulation of the brain, or administration of aversive electrical stimuli for behaviour modification treatment. It is not invasive, no tissue is incised or removed, and therefore it is not a surgical procedure. It does not result in any

gross anatomical or histological lesions producing permanent brain damage.

It is believed that the brain's control of the seizure may be what makes ECT efficacious (Abrams, 2002). Seizure induction as a treatment for psychiatric illness was based upon early observations that symptoms of dementia praecox (schizophrenia) were diminished when patients developed epilepsy and that patients with epilepsy had a low incidence of psychosis (Mankad, Beyer, Weiner and Krystal, 2010).

Recent neuroscience reports have verified that repeated seizures create new neurons and enhance gliosis providing a further explanation as to why induced seizures are highly antimelancholic (Bolwig and Madsen, 2007).

REFERENCES

- Abrams, R. (2002). *Electroconvulsive Therapy*, 4th edition. New York: Oxford University Press.
- Barker, J.C., and Miller, M. (1968). Aversion therapy for compulsive gambling. *The Journal of Nervous and Mental Disease*, 146(4), 285–302. Retrieved from http://journals.lww.com/jonmd/Fulltext/1968/04000/AVERSION_THERAPY_FOR_COMPULSIVE_GAMBLING_.2.aspx.
- Bolwig, T.G., and Madsen, T.M. (2007). Electroconvulsive therapy in melancholia: the role of hippocampal neurogenesis. *Acta Psychiatrica Scandinavica Suppl*, 433, 130–135. doi:10.1111/j.1600-0447.2007.00971.x.
- Brockie, J. (2013). Electro-shock. *SBS Insight*. Retrieved from www.sbs.com.au/news/insight/tvepisode/electroshock.
- Bucci, N. (2009). Patient fears shock therapy. Retrieved from www.bendigoadvertiser.com.au/story/705391/patient-fears-shock-therapy.
- Church of Scientology. (2015). Citizens Commission on Human Rights (CCHR). Retrieved from www.cchr.org/cchr-reports/citizen-commission-on-human-rights/introduction.html.
- De Brito, K. (2004). It has a brutal history. We don't know if it works. So why are we still using electric shock therapy? *Australian Report Marie Claire Magazine*.
- Dukakis, K., and Tye, L. (2006). *Shock: The Healing Power of Electroconvulsive Therapy*. New York: Penguin.
- Feldman, M.P. (1966). Aversion therapy for sexual deviations: A critical review. *Psychological Bulletin*, 62(2), 65–79. doi:10.1037/h0022913.
- Fink, M. (1985). Convulsive therapy. *Convulsive Therapy*, 1(1), 1–3.
- Fink, M. (2009). *Electroconvulsive Therapy: A Guide for Professionals and Their Patients*. New York: Oxford University Press.
- Kesey, K. (1962). *One Flew Over the Cuckoo's Nest*. Retrieved from www.goodreads.com/author/show/7285.Ken_Kesey.
- McCall, W.V., Kellner, C.H., and Fink, M. (2014). Convulsive therapy and the *Journal of ECT*: 30 years of publication and continuing. *Journal of ECT*, 30(1), 1–2. doi:10.1097/YCT.000000000000107.
- Mankad, M.V., Beyer, J.L., Weiner, R.D., and Krystal, A. (2010). *Clinical Manual of Electroconvulsive Therapy*. Washington, DC: American Psychiatric Publishing.
- Marquis, J.N. (1970). Orgasmic reconditioning: changing sexual object choice through controlling masturbation fantasies. *Journal of Behavior Therapy and Experimental Psychiatry*, 1(4), 263–271. doi:10.1016/0005-7916(70)90050-9.
- Morrison, L. (2009). ECT: shocked beyond belief. *Australasian Psychiatry*, 17(2), 164–167. doi:10.1080/10398560802596090.
- Nutt, D.J., and Glue, P. (1993). The neurobiology of ECT: animal studies. In Coffey, E.C. (Ed.), *The Clinical Science of Electroconvulsive Therapy* (Vol. 38, pp. 213–234). Washington, DC: American Psychiatric Press.
- Torpey, N. (2016). Special investigation: Shock treatment: Alarming spike in risky electroconvulsive therapy on children. *Sunday Mail* (Brisbane, Australia).
- Wilson, G.T., and Davison, G.C. (1969). Aversion techniques in behavior therapy: some theoretical and metatheoretical considerations. *Journal of Consulting and Clinical Psychology*, 33(3), 327–329. doi:10.1037/h0027597.

Equipment

■ History: ECT devices	14
■ ECT device characteristics	19

HISTORY: ECT DEVICES

Cerletti and Bini designed and built the first ECT device in Rome, Italy, in 1937 (Metastasio and Dodwell, 2013). In 1941, Dr H.M. Birch, with the assistance of C.R.Paul from the physics department at the University of Adelaide, built the first ECT device in Australia, which was used to treat patients with manic depression and schizophrenia at Glenside Hospital in South Australia (Website for the Virtual Museum, 2015).

C.R. Paul manufactured a second device in 1943 for Dr Dibden, who also worked at Glenside Hospital.

Dr H.M. Birch published an article in the *Medical Journal of Australia* on 20 June 1942 describing the physics involved in constructing the device, including a circuit diagram and a review of the first nine months of clinical use (Website for the Virtual Museum, 2015). The device used contemporary telecommunications technology incorporating a telephone dial that allowed the stimulus length to be varied. There were a number of different device manufacturers in Australia.

Photo 1.3.1 illustrates an ECT device manufactured by Techtron Appliances in Melbourne, while Photo 1.3.2 illustrates an ECT device manufactured by “BOTH” and sold in Adelaide and Sydney.

Dr H.M. Birch recognised that the effective dose of the alternating current may differ between



Photo 1.3.1 Dial-up ECT device

Source: Rodman & Kelame electro medical instrument makers, Sydney



Photo 1.3.2 Dial-up ECT device with history, Morisset Hospital Historical Society, "BOTH" electroconvulsive therapy machine (ECT)

"There are several types of machines manufactured. An anaesthetic and muscle relaxant is given followed by artificial ventilation with oxygen. A soft mouth guard protects the teeth during the induced convulsion. Electrodes are covered with gauze wadding and soaked in saline to improve conduction then positioned across the skull. The telephone dial is dialed from the number '9' position to induce the current, which causes a controlled convulsion. ECT can be an effective treatment for severe depression, catatonia, some forms of mania and schizophrenia.

Why this treatment is so effective is still mysterious. The brain functions using electrochemical messages, and it is thought that ECT-induced seizures interrupt these messages and 'reset' the brain."



Photo 1.3.3 Sine wave ECT device

patients owing to the impact of the skin, tissue and bony structures, allowing the stimulus to be adjusted, an early acknowledgement of seizure threshold (Website for the Virtual Museum, 2015).

The telephone dial-up device from the 1950s illustrated in Photos 1.3.1 and 1.3.2 was used at Morisset Hospital until the 1960s, when it was replaced by a sine wave ECT device shown in Photo 1.3.3.

Sine wave devices such as that illustrated in Photo 1.3.3 replaced the dial-up instrument in most



Photo 1.3.4 MECTA Model C

hospitals administering ECT at that time around the world.

Oregon Health Sciences University (OHSU), Portland, Oregon, developed the original MECTA, an acronym meaning Monitored Electro-Convulsive Therapy Apparatus, to counter the ECT stigma that had ramped up against ECT in the 1970s within the USA. Dr Paul Blachly was concerned that patients were getting inferior treatment and required a new device with built-in safety features: a self-test to assure adequate patient electrode connections before being allowed to treat to avoid skin burns, a bidirectional pulse width one tenth of the energy of competitive Medcraft and Reider sine wave devices, and two monitoring channels. MECTA (MECTA Corporation, 2015). Such innovation changed the practice of ECT. What is disturbing but common in the development of ECT is how slowly new technology gets incorporated into clinical practice. This is well illustrated in the community study of ECT, where some centres continued to use sine wave devices across the state of New York even after the year 2000 (Sackeim et al., 2007).

The original MECTA Model C device, illustrated in Photo 1.3.4, was developed in 1973 by Oregon Health Sciences University and sold by the MECTA Corporation from 1980. The instrument was innovative as it was the first device to incorporate monitored electroencephalogram (EEG) and electrocardiogram (EKG) brief pulse into an ECT device. MECTA Model D, shown in Photo 1.3.5, was developed by the MECTA Corporation and introduced in 1981 and was quickly followed by



Photo 1.3.5 MECTA Model D



Photo 1.3.6 MECTA Model JR-1

Models JR-1, shown in Photo 1.3.6, JR-2, SR-1, illustrated in Photo 1.3.7, and SR-2, which were developed by MECTA in collaboration with the Columbia University and released in 1985, a collaboration that lasted until 2006. These devices dominated the US market for 13 years and lead to substantial improvement in clinical practice. These devices were eventually replaced by new devices in 1998 (MECTA Corporation, 2015).

In the United Kingdom, the device market was dominated by ECTRON Limited, which was set up by a psychiatrist, Robert Russell, in 1950. Devices have evolved from the Ectnos and Ectonustim series to the current model Ectonustim Series 6+ ECT device (ECTRON Limited, 2016). In more recent years, the UK, like many other ECT services worldwide, has incorporated Thymatron and MECTA devices into their practice.



Photo 1.3.7 MECTA Model SR-1

In Australia, the sine wave devices were replaced with a Kabtronics unit, which incorporated brief-pulse, square wave technology, an innovation that reduced the level of cognitive impairment in patients having ECT (Spanis and Squire, 1981). The Kabtronics device is illustrated in Photo 1.3.8.

It was manufactured locally using electrical fittings manufactured by Clipsal, a large Australian company. The device utilised a Y-shaped, fixed handheld unilateral electrode that incorporated both mental discs with a switch built into the top of the yoke, allowing the stimulus to be delivered by direct pressure from the thumb, illustrated in Photo 1.3.9. In many centres, these electrodes replaced the rubber band and metal disc system that was commonly used at that time and is illustrated in Photo 1.3.10.

Theoretically it was a useful innovation; however, the electrodes could not be adjusted to suit




Photo 1.3.10 Rubber band and metal electrodes



Photo 1.3.11 Thymatron DGx ECT device



Photo 1.3.8 Kabtronics ECT device



Photo 1.3.9 Kabtronics ECT electrodes

individual patient variability, with treatment often being administered using the wrong electrode site, Lancaster rather than the d'Elia position (d'Elia, 1970; Lancaster, Steinert and Frost, 1958). There were safety issues concerning the built-in switch, which could be easily pushed accidentally.

Incorporating an EEG into the ECT instrument increased the clinical power to deliver effective ECT rather than sole reliance on the length of motor end point, a feature that has failed to have clinical utility (Abrams, 2002; Mayer, 2006).

The EEG facilitates discrimination between electrode positions and different stimulus doses. It can predict treatment response and changes in the EEG that may indicate threshold changes highlighting the need to increase the stimulus dose or reduce the anaesthetic induction agent. Postictal suppression or electrical silence is an important feature of the EEG that has strong clinical relevance as it has been shown to correlate with treatment efficacy (Mayer, 2006), illustrated in EEG 5.5.9.

Photos 1.3.11 and 1.3.12 illustrate two models of the Thymatron DGx device, which incorporated a two-channel EEG that was stored on a dual graph



Photo 1.3.12 More recent Thymatron DGx ECT device

paper trace, developed in the late 1980s by Somatics, a US-based company (Somatics L.L.C., 2015). This was the first device widely used in Australia that incorporated an EEG with a stimulus that had a constant-current, square wave with a pulse width of 1.5 milliseconds (ms). A few years after it was released, Somatics released the Flexidial, which plugged into the back of the device, as shown in Photo 1.3.13. The Flexidial enabled the operator to change the frequency and pulse width and allowed the device to administer stimuli up to double the millicoulombs (mC) from 504 mC to 1008 mC (Somatics L.L.C., 2015).



Photo 1.3.13 Flexidial for Thymatron DGx ECT device

It incorporated one- or two-channel EEG recording and calculated objective markers of seizure adequacy that were printed out at the end of the seizure when the recording device was turned off. It was the first attempt to provide objective measures to aid the clinician in determining whether a seizure had been of good quality or not. In the mid-1990s the Thymatron System IV replaced the Thymatron DGx. This device is illustrated in Photo 1.3.14.

In 1998, the MECTA Corporation released a series of competitive devices, the spECTrum 4000 and 5000M and Q, which replaced the SR and JR models. Like the Thymatron, these devices incorporated EEG data analysis to aid the clinician. The spECTrum 4000 was fully featured except it did not have EEG capacity, whereas the 5000 models had the capacity for six-channel recording. An early spECTrum 5000M device is illustrated in Photo 1.3.15.

The MECTA spECTrum 4000M and 5000M devices were similar to the Thymatron System IV, changing all of the stimulus parameters with a single dial to determine the stimulus charge. The MECTA spECTrum 4000Q and 5000Q required the ECT practitioner to set each stimulus parameter –



Photo 1.3.14 Thymatron System IV ECT device



Photo 1.3.15 MECTA spECTrum 5000M ECT device



Photo 1.3.16 MECTA spECTrum 5000Q ECT device

pulse width, duration, frequency and voltage – separately. The spECTrum 5000Q is illustrated in Photo 1.3.16. Photo 1.3.17 illustrates the MECTA spECTrum 5000 digital display options.

In Australia, the common use of MECTA devices in clinical practice has been a recent phenomenon with the release of the spECTrum 5000M and Q. MECTA SR and JR devices were used in a few centres but there were no ELCRON devices sold, with the market being dominated by a locally produced device made by Kabtronics.




Photo 1.3.17 MECTA spECTrum 5000Q ECT device with digital display

The new Thymatron System IV device had other features that were clinically useful. “System IV” referred to the capacity to record information from four different channels, generating a more comprehensive trace: two EEG channels as well as channels for an electromyogram (EMG) and an electrocardiogram (ECG). The Thymatron System IV device generated a larger number of markers of seizure adequacy, which were designed to assist the clinician in assessing the adequacy of the seizure obtained. Tables 5.5.1 and 5.5.2 illustrate the markers of seizure adequacy for the Thymatron DGx and Table 5.5.3 for the MECTA spECTrum 5000 devices.

ECT DEVICE CHARACTERISTICS

The Thymatron System IV, MECTA spECTrum 5000 and Ectonustim Series 6 share similar specifications. They all deliver a constant current while the voltage varies according to the impedance (electrical resistance) offered by the head of the patient during the application of the electrical stimulus. The advantage of a constant-current delivery system is that the clinician is guaranteed a predetermined charge, independent of fluctuations and impedance. The delivered charge will be inversely proportional to the impedance in the circuit, following Ohm’s law (American Psychiatric Association, 2001). Careful skin preparation of all sites is required to maximise electrode contact before the electrodes are attached to minimise the impedance and reduce voltage and the risk of burns. All devices offer handheld electrodes, with the ECRON and MECTA incorporating the treatment button within the handle of one treating electrode so that the stimulus can be applied without touching the device. Care must be taken not to accidentally hit the switch prematurely. The Thymatron System IV is the only device to offer disposable treatment electrodes, an innovation that reduces stigma, heralding ECT as a modern medical practice.

All devices have the potential for recording an EEG. The Ectonustim Series 6 device and the MECTA 4000 series do not have built-in EEG recording facilities. Both the MECTA 5000 series

and the Thymatron System IV device have built-in channels for recording. All MECTA 5000 devices print only two recorded channels but have the capacity to store six channels of information. By contrast, the Thymatron “System IV” refers to its capacity to record information from four different channels generating a more comprehensive trace: two EEG channels as well as channels for an electromyogram (EMG) and an electrocardiogram (ECG). The device also generated a larger number of markers of seizure adequacy, which were designed to assist the clinician in assessing the adequacy of the seizure obtained.


All devices offer similar stimulus ranges. The Ectonustim Series 6 offers a range from 50 to 1000 millicoulombs and claims to have a feature called Auto Crescendo, which delivers an advanced 0.25-second auto crescendo onset that gently eases the patients into ECT (ECRON Limited, 2016). This device also claims an advantage over the other devices with its split pulse technology, where each pulse group consists of a single 1-millisecond (ms) pulse followed by two pulses of 0.6 ms as well as offering a mode for non-convulsive stimulation, a low-voltage unidirectional sine wave stimulus that may be used to give a counter-stimulus after ECT. The Ectonustim Series 6+ delivers different ranges of ECT output: low range, 50 to 750 mC at 750 mA, and high range, 200 to 1000 mC at 900 mA (ECRON Limited, 2016).

The MECTA spECTrum 5000 has a stimulus range from 22.9 to 1152 millicoulombs, whereas the Thymatron System IV range is from 25 to 1008 millicoulombs.

All devices have the capacity to measure static and dynamic impedance to ensure effective treatment. Static impedance needs to be manually assessed through pushing a button on the Thymatron device, whereas it is automatically displayed on the other two devices.

REFERENCES

- Abrams, R. (2002). *Electroconvulsive Therapy*, 4th edition. New York: Oxford University Press.
- American Psychiatric Association. (2001). *The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging: A Task Force Report*, 2nd edition. Washington, DC: American Psychiatric Association.
- d’Elia, G. (1970). Unilateral electroconvulsive therapy. *Acta Psychiatrica Scandinavica, Supplement 215*, 1–98.
- ECRON Limited. (2016). Ectonustim Series 6+.
- Lancaster, N.P., Steinert, R.R., and Frost, I. (1958). Unilateral electro-convulsive therapy. *Journal of Mental Science*, 104, 221–227.
- Mayer, P. (2006). Ictal electroencephalographic characteristics during electroconvulsive therapy: a review of determination and clinical relevance. *Journal of ECT*, 22(3), 213–217.
- MECTA Corporation. (2015). spECTrum 5000Q – MECTA Corp. Retrieved from www.mectacorp.com/spectrum-5000Q.html.
- Metastasio, A., and Dodwell, D. (2013). A translation of “L’Elettroshock” by Cerletti and Bini, with an introduction. *The European Journal of Psychiatry*, 27(4). doi:10.4321/S0213-61632013000400001.
- Sackeim, H.A., Prudic, J., Fuller, R., Keilp, J., Lavori, P.W., and Olfson, M. (2007). The cognitive effects of electroconvulsive therapy in community settings. *Neuropsychopharmacology*, 32(1), 244–254. doi:10.1038/sj.npp.1301180.
- Somatics L.L.C. (2015). Somatics, LLC – manufacturer of the Thymatron ECT machine. Retrieved from www.thymatron.com/main_home.asp.
- Spanis, C.W., and Squire, L.R. (1981). Memory and convulsive stimulation: effects of stimulus waveform. *American Journal of Psychiatry*, 138(9), 1177–1181. Retrieved from www.ncbi.nlm.nih.gov/pubmed/7270720.
- Website for the Virtual Museum. (2015). Electroconvulsive therapy (ECT): The South Australian experience: 1942. Retrieved from [http://samhs.org.au/Virtual Museum/Medicine/drugs_nonsurg/ect/ect.html](http://samhs.org.au/Virtual%20Museum/Medicine/drugs_nonsurg/ect/ect.html).



CHAPTER 2

Knowledge



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

History: treatment of mental illness

■ Trepanning: early psychosurgery?	23
■ Bloodletting	24
■ Pharmacology	25
■ Phrenology	26
■ Early 1800s	27
■ Electricity	29

From very early times, physicians, witch doctors, apothecaries and charlatans have searched for methods of understanding and improving people's general health and sense of well-being or treating mental illness specifically. The principal methods employed included: trepanning, phlebotomy/purging, pharmacology, phrenology and electricity.

TREPPANNING: EARLY PSYCHOSURGERY?

Trepanning was a technique that involved cutting holes into the skull. Trepanning tools, a skull and a photograph of the outcome are illustrated in Photos 2.1.1 and 2.1.2. From ancient times, trepanning had an enthusiastic following for many years and we know it was carried out successfully as trepanned skulls of early man have been found with healed bone edges. Although still used for



Photo 2.1.1 Trepanning with skull




Photo 2.1.2 *Trepanning with tools and image*

legitimate reasons – for example, depressed fractures, removing blood clots and neurosurgery – it was particularly popular in the middle ages for treatment of vague headaches and to release evil spirits that were blamed for causing various derangements of the mind. It continued to be practised regularly, well into the eighteenth century.

The piece of bone removed was even pulverised and drunk as a therapeutic elixir when mixed with various liquids! There is no evidence that trepanation actually had any benefit for treatment of mental illness and in the early days of primitive instruments, no anaesthetic and poor hygiene the risks would have far outweighed any possible benefit.

BLOODLETTING

Bloodletting tools and a map that was used to guide treatment are illustrated in Photo 2.1.3. Bloodletting was one of medicine's earliest and most widely practised treatments. Even before the fifth century AD, surgeons and barbers practised bloodletting, which is reflected in the barber's red and white pole, red signifying blood and white the tourniquet.

"Cutting of a vein", or "airing a vein", was a logical treatment when based on a prevailing theory of four bodily "humours" – blood, phlegm, yellow



Photo 2.1.3 *Bloodletting*

bile and black bile. Excessive humours caused fever, inflammation and general debility so purging or bloodletting would rid the patient of this excess and restore the balance. Good health was just a lancet puncture away.

It was particularly popular in the eighteenth and nineteenth centuries and is still used in some cultures, where it is often combined with "cupping", where the application of a heated "cup" results in an engorged area on the skin due to the vacuum created as the air in the cup cooled.

Generally an artery or vein was punctured with a lancet for a good yield and an average quantity of 500–900 ml to get rid of bad humours continued to the point of faintness. It was often permanent; for example, King Charles II succumbed to bleeding by physicians in 1685. On 14 December 1799, George Washington went to his death with a throat infection after receiving a series of medical procedures including draining nearly 40% (9 pints) of his blood.

Various instruments were used, the oldest being just a lancet. The lancet was a simple blade,